Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
Z129382-25mg | 25mg | In stock | $9.90 | |
Z129382-100mg | 100mg | In stock | $14.90 | |
Z129382-1g | 1g | In stock | $28.90 | |
Z129382-5g | 5g | In stock | $98.90 | |
Z129382-25g | 25g | In stock | $444.90 |
Highly potent bisphosphonate. FPP synthase inhibitor.
Synonyms | 70HZ18PH24 | CAS-118072-93-8 | SR-05000001436 | (1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acid | D08689 | FT-0601384 | GTPL3177 | NCGC00159521-02 | s1314 | AB01273947-03 | 1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyldiphosphonic acid | AB01 |
---|---|
Specifications & Purity | Moligand™, ≥99% |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | INHIBITOR |
Mechanism of action | Farnesyl diphosphate synthase inhibitor |
ALogP | -4.3 |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Pubchem Sid | 488184180 |
---|---|
Pubchem Sid Url | https://pubchem.ncbi.nlm.nih.gov/substance/488184180 |
IUPAC Name | (1-hydroxy-2-imidazol-1-yl-1-phosphonoethyl)phosphonic acid |
INCHI | InChI=1S/C5H10N2O7P2/c8-5(15(9,10)11,16(12,13)14)3-7-2-1-6-4-7/h1-2,4,8H,3H2,(H2,9,10,11)(H2,12,13,14) |
InChi Key | XRASPMIURGNCCH-UHFFFAOYSA-N |
Canonical SMILES | C1=CN(C=N1)CC(O)(P(=O)(O)O)P(=O)(O)O |
Isomeric SMILES | C1=CN(C=N1)CC(O)(P(=O)(O)O)P(=O)(O)O |
PubChem CID | 68740 |
Molecular Weight | 272.09 |
ChEMBL Ligand | CHEMBL924 |
---|---|
DrugBank Ligand | DB00399 |
Wikipedia | Zoledronate |
CAS Registry No. | 118072-93-8 |
PubChem CID | 68740 |
ChEBI | CHEBI:46557 |
RCSB PDB Ligand | ZOL |
PEP | zoledronic acid |
Immunopaedia Search | zoledronic acid |
DrugCentral Ligand | 2868 |
PubChem SID | 488184180 |
Enter Lot Number to search for COA:
Find and download the COA for your product by matching the lot number on the packaging.
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
J2414675 | Certificate of Analysis | Oct 08, 2024 | Z129382 |
J2414669 | Certificate of Analysis | Oct 08, 2024 | Z129382 |
J2414668 | Certificate of Analysis | Oct 08, 2024 | Z129382 |
J2414667 | Certificate of Analysis | Oct 08, 2024 | Z129382 |
J2414643 | Certificate of Analysis | Oct 08, 2024 | Z129382 |
H2406230 | Certificate of Analysis | Mar 02, 2024 | Z129382 |
G23221034 | Certificate of Analysis | Jul 07, 2023 | Z129382 |
H2429022 | Certificate of Analysis | Jul 07, 2023 | Z129382 |
G23221042 | Certificate of Analysis | Jul 07, 2023 | Z129382 |
G23221041 | Certificate of Analysis | Jul 07, 2023 | Z129382 |
G23221040 | Certificate of Analysis | Jul 07, 2023 | Z129382 |
G23221038 | Certificate of Analysis | Jul 07, 2023 | Z129382 |
G23221037 | Certificate of Analysis | Jul 07, 2023 | Z129382 |
G23221033 | Certificate of Analysis | Jul 07, 2023 | Z129382 |
G23221028 | Certificate of Analysis | Jul 07, 2023 | Z129382 |
G23221017 | Certificate of Analysis | Jul 07, 2023 | Z129382 |
C2415131 | Certificate of Analysis | Jul 07, 2023 | Z129382 |
C2130027 | Certificate of Analysis | Jan 12, 2023 | Z129382 |
C2130024 | Certificate of Analysis | Jan 12, 2023 | Z129382 |
C2130026 | Certificate of Analysis | Jan 12, 2023 | Z129382 |
D1912082 | Certificate of Analysis | Dec 06, 2022 | Z129382 |
F2230307 | Certificate of Analysis | Jul 04, 2022 | Z129382 |
F2215113 | Certificate of Analysis | Jun 23, 2022 | Z129382 |
E2312259 | Certificate of Analysis | Jun 23, 2022 | Z129382 |
C2011020 | Certificate of Analysis | Jan 27, 2022 | Z129382 |
Solubility | DMSO 0.004 mg/mL Water <1 mg/mL Ethanol <1 mg/mL |
---|
Pictogram(s) | GHS07 |
---|---|
Signal | Warning |
Hazard Statements | H319:Causes serious eye irritation H317:May cause an allergic skin reaction |
Precautionary Statements | P261:Avoid breathing dust/fume/gas/mist/vapors/spray. P305+P351+P338:IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do - continue rinsing. P280:Wear protective gloves/protective clothing/eye protection/face protection. P302+P352:IF ON SKIN: wash with plenty of water. P321:Specific treatment (see ... on this label). P501:Dispose of contents/container to ... P272:Contaminated work clothing should not be allowed out of the workplace. P333+P313:IF SKIN irritation or rash occurs: Get medical advice/attention. P362+P364:Take off contaminated clothing and wash it before reuse. P264+P265:Wash hands [and …] thoroughly after handling. Do not touch eyes. P337+P317:If eye irritation persists: Get medical help. |
1. Wanzhen Li, Yongqi Yang, Jun Wang, Ting Ge, Shuixia Wan, Lin Gui, Yugui Tao, Ping Song, Liangjun Yang, Fei Ge, Weiwei Zhang. (2024) Establishment of bone-targeted nano-platform and the study of its combination with 2-deoxy-d-glucose enhanced photodynamic therapy to inhibit bone metastasis. Journal of the Mechanical Behavior of Biomedical Materials, 150 (106306). [PMID:38091923] [10.1016/j.jmbbm.2023.106306] |
2. Yao Duan, Chanyuan Jin, Yuwei Wu, Yan Chen, Minjuan Zhang, Jun Qian, Ting Shuai, Jian Li, Huimin Chen, Dan Li. (2023) CREB1 alleviates the apoptosis and potentiates the osteogenic differentiation of zoledronic acid-treated human periodontal ligament stem cells via up-regulating VEGF. TISSUE & CELL, 85 (1): (102223). [PMID:37776785] [10.1016/j.tice.2023.102223] |
3. Ting Ge, Zhang Weiwei, Fei Ge, Longbao Zhu, Ping Song, Wanzheng Li, Lin Gui, Wan Dong, Yugui Tao, Kai Yang. (2022) A bone-targeting drug delivery vehicle of a metal–organic framework conjugate with zoledronate combined with photothermal therapy for tumor inhibition in cancer bone metastasis. Biomaterials Science, 10 (7): (1831-1843). [PMID:35253030] [10.1039/D1BM01717A] |
1. Lu H et al.. (2021) B7-H3 confers resistance to V?9Vd2 T cell-mediated cytotoxicity in human colon cancer cells via the STAT3/ULBP2 axis.. Cancer Immunol Immunother, 70 (5): (1213-1226). [PMID:33119798] |
2. Lu H et al.. (2020) B7-H3 inhibits the IFN-?-dependent cytotoxicity of V?9Vd2 T cells against colon cancer cells.. Oncoimmunology, 9 (1748991). [PMID:32363121] |
3. Wanzhen Li, Yongqi Yang, Jun Wang, Ting Ge, Shuixia Wan, Lin Gui, Yugui Tao, Ping Song, Liangjun Yang, Fei Ge, Weiwei Zhang. (2024) Establishment of bone-targeted nano-platform and the study of its combination with 2-deoxy-d-glucose enhanced photodynamic therapy to inhibit bone metastasis. Journal of the Mechanical Behavior of Biomedical Materials, 150 (106306). [PMID:38091923] [10.1016/j.jmbbm.2023.106306] |
4. Yao Duan, Chanyuan Jin, Yuwei Wu, Yan Chen, Minjuan Zhang, Jun Qian, Ting Shuai, Jian Li, Huimin Chen, Dan Li. (2023) CREB1 alleviates the apoptosis and potentiates the osteogenic differentiation of zoledronic acid-treated human periodontal ligament stem cells via up-regulating VEGF. TISSUE & CELL, 85 (1): (102223). [PMID:37776785] [10.1016/j.tice.2023.102223] |
5. Ting Ge, Zhang Weiwei, Fei Ge, Longbao Zhu, Ping Song, Wanzheng Li, Lin Gui, Wan Dong, Yugui Tao, Kai Yang. (2022) A bone-targeting drug delivery vehicle of a metal–organic framework conjugate with zoledronate combined with photothermal therapy for tumor inhibition in cancer bone metastasis. Biomaterials Science, 10 (7): (1831-1843). [PMID:35253030] [10.1039/D1BM01717A] |